Medial EarlySign

About:

Medial EarlySign helps healthcare clients with their early detection and prevention of high-burden diseases using routine, existing EHR data

Website: http://earlysign.com/

Twitter/X: MedialEarlySign

Top Investors: Horizons Ventures, aMoon Fund, Horizon Ventures, Marius Nacht, Nir Kalkstein

Description:

Medial EarlySign develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. Called AlgoMarkers, its predictive engines are built in collaboration with healthcare organizations, through the combination of 10s of millions of patient years-worth of data, clinical rigor and some of the most brilliant algorithmic minds. The company develops clinical decision support and population health solutions that can assist in the early prediction of clinical outcomes related to cancers, metabolic, immune and infectious diseases. These tools are designed to place at the fingertips of healthcare organizations only those insights that could prove critical in disease management and prevention empowering them with proactive, predictive and personalized care management capabilities

Total Funding Amount:

$50M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Hod Hasharon, HaMerkaz, Israel

Founded Date:

2009-01-01

Contact Email:

solutions(AT)earlysign.com

Founders:

Nir Kalkstein, Ofer Ariely, Ori Geva

Number of Employees:

11-50

Last Funding Date:

2018-03-06

IPO Status:

Private

© 2024 MyAiNote.com